Middle East Journal of Cancer

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Surface Malignancy: Initial Report from Shiraz Surgical Oncology Group

Document Type : Original Article(s)

Authors

Majid Akrami 1
Samad Khezri 1
Sedigheh Tahmasebi 1
Mohammad Yasin Karami 1
Zahra Shiravani 2, 3
Vahid Zangouri 1
Abdolrasoul Talei 1
Nazanin Karimaghaei 4

1 Breast Diseases Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Gynecology Oncology Division, Department of Obstetrics and Gynecology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran

3 Maternal-Fetal Medicine Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

4 Core Medical Trainee, Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, U.K.

https://doi.org/10.30476/mejc.2021.87830.1440
Abstract
Background: Hyperthermic intraperitoneal chemotherapy (HIPEC) is increasingly used to treat peritoneal carcinomatosis (PC). The objective was to evaluate the outcomes of cytoreductive surgery (CRS) and HIPEC in our center.
Method: In this retrospective study, data were collected from 43 patients with PC who underwent CRS-HIPEC in 2016 at Faghihi Hospital of Shiraz University of Medical Sciences. Outcomes were collected and analyzed. Analyses were conducted through SPSS 23. P-value < 0.05 was considered to be statistically significant.
Results: The mean age of the patients was 52.23 پ} 11.82 years. The participants in the study analysis consisted of 36 female (83.7%) and seven male patients (16.3%). The most common primary tumor was ovarian cancer (62.8%). Completeness of the cytoreduction score of CC0/CC1 was obtained in 87.7% of the patients. The 1- and 3- year overall survivals were 88% and 60%, respectively.
Conclusion: Our study supports that employing CRS and HIPEC for PC is feasible with acceptable morbidity in our center.

Keywords

Peritoneal malignancy
Drug therapy
Cytoreductive surgical procedures

How to cite this article:

Akrami M, Khezri S, Tahmasebi S, Karami MY, Shiravani Z, Zangouri V, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy: Initial report from Shiraz surgical oncology group. Middle East J Cancer. 2022;13(3):458-65. doi: 10.30476/mejc.2021.87830.1440.

  1. Sugarbaker PH. Prevention and treatment of peritoneal metastases: a comprehensive review. Indian J Surg Oncol. 2019;10(1):3-23. doi: 10.1007/s13193-018-0856-1.
  2. Nikeghbalian S, Nikoupour H, Dehghani M, Karami MY, Hemati R. Cytoreductive surgery and hyperthermic intraoperative chemotherapy for management of peritoneal carcinomatosis. Arch Iran Med. 2018;21(4):158-63.
  3. Sugarbaker PH. New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome? Lancet Oncol. 2006;7(1):69-76. doi: 10.1016/S1470-2045(05)70539-8.
  4. Sugarbaker PH, Turaga KK, Alexander HR Jr, Deraco M, Hesdorffer M. Management of malignant peritoneal mesothelioma using cytoreductive surgery and perioperative chemotherapy. J Oncol Pract. 2016;12(10):928-935. doi: 10.1200/JOP.2016.011908.
  5. Aoyagi T, Terracina KP, Raza A, Takabe K. Current treatment options for colon cancer peritoneal carcinomatosis. World J Gastroenterol. 2014;20(35):12493. doi: 10.3748/wjg.v20.i35.12493.
  6. Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, et al. Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460. doi: 10.1200/JCO.2014.55.9898.
  7. Koh JL, Yan TD, Glenn D, Morris DL. Evaluation of preoperative computed tomography in estimating peritoneal cancer index in colorectal peritoneal carcinomatosis. Ann Surg Oncol. 2009;16(2):327-33.
  8. Strasberg SM. Nomenclature of hepatic anatomy and resections: a review of the Brisbane 2000 system. J Hepatobiliary Pancreat Surg. 2005;12(5):351-5. doi:10.1007/s00534-005-0999-7.
  9. Sugarbaker PH. Intraperitoneal chemotherapy and cytoreductive surgery for the prevention and treatment of peritoneal carcinomatosis and sarcomatosis. Semin Surg Oncol. 1998;14(3):254-61. doi: 10.1002/(sici)1098-2388(199804/05)14:3<254::aid-ssu10>3.0.co;2-u.
  10. Carmignani CP, Esquivel J, Sugarbaker PH. Cytoreductive surgery and intraperitoneal chemotherapy for the treatment of peritoneal surface malignancy. Revista de Oncología. 2003;5(4):192-8.
  11. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205. doi: 10.1097/01.sla.0000133083.54934.ae.
  12. Muñoz-Casares FC, Medina-Fernández FJ, Arjona-Sánchez Á, Casado-Adam Á, Sánchez-Hidalgo JM, Rubio MJ, et al. Peritonectomy procedures and HIPEC in the treatment of peritoneal carcinomatosis from ovarian cancer: Long-term outcomes and perspectives from a high-volume center. Eur J Surg Oncol. 2016;42(2):224-33. doi: 10.1016/j.ejso.2015.11.006.
  13. Chua TC, Moran BJ, Sugarbaker PH, Levine EA, Glehen O, Gilly FN, et al. Early-and long-term outcome data of patients with pseudomyxoma peritonei from appendiceal origin treated by a strategy of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. J Clin Oncol. 2012;30(20):2449-56. doi: 10.1200/JCO.2011.39.7166.
  14. Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Ann Surg oncol. 2015;22(5):1686-93. doi: 10.1245/s10434-014-3978-x.
  15. Glehen O, Gilly FN, Arvieux C, Cotte E, Boutitie F, Mansvelt B, et al. Peritoneal carcinomatosis from gastric cancer: a multi-institutional study of 159 patients treated by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy. Ann Surg Oncol. 2010;17(9):2370-7.
  16. Spiliotis J, Halkia E, De Bree E. Treatment of peritoneal surface malignancies with hyperthermic intraperitoneal chemotherapy—current perspectives. Curr Oncol. 2016;23(3):e266. doi:10.3747/co.23.2831.
  17. van Driel WJ, Koole SN, Sikorska K, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, et al. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer. N Engl J Med. 2018;378(3):230-40. doi: 10.1056/NEJMoa1708618.
  18. Huo YR, Richards A, Liauw W, Morris DL. Hyperthermic intraperitoneal chemotherapy (HIPEC) and cytoreductive surgery (CRS) in ovarian cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2015;41(12):1578-89. doi: 10.1016/j.ejso.2015.08.172.
  19. Wang Y, Ren F, Chen P, Liu S, Song Z, Ma X. Effects of CytoReductive surgery plus hyperthermic IntraPEritoneal chemotherapy (HIPEC) versus CytoReductive surgery for ovarian cancer patients: A systematic review and meta-analysis. Eur J Surg Oncol. 2019;45(3):301-9. doi: 10.1016/j.ejso.2018.10.528.
  20. Robella M, Vaira M, Cinquegrana A, De Simone M. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: morbidity and postoperative outcomes. Minerva Chir. 2019;74(3):195-202. doi: 10.23736/s0026-4733.18.07649-6.
  21. Piso P, Nedelcut SD, Rau B, Königsrainer A, Glockzin G, Ströhlein MA, et al. Morbidity and mortality following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: Data from the DGAV StuDoQ registry with 2149 consecutive patients. Ann Surg Oncol. 2019;26(1):148-54. doi: 10.1245/s10434-018-6992-6.

Home

Guide for Authors

Submit Manuscript

Guide for Reviewers

Contact Us